Helaina Raises $20 Million In Series A To Scale Production Of Its Human Milk Proteins Using Precision Fermentation Co-Led By Spark Capital And Siam Capital
Helaina Raises $20 Million In Series A To Scale Production Of Its Human Milk Proteins Using Precision Fermentation Co-Led By Spark Capital And Siam Capital
11/19/21, 7:30 AM
Money raised
$20 million
Round Type
series a
Helaina, the company using precision fermentation to recreate immune-equivalent proteins previously only available in breast milk, announced today it has raised $20 million in Series A funding. The round was co-led by Spark Capital and Siam Capital, with additional investment from Primary Venture Partners, Plum Alley Investments, Tom Williams, Hannah Bronfman, Gabrielle Union, Matt Rutler and Barrel Ventures, among other strategic partners. The new infusion of funds, which brings total capital raised to $24.6 million, will be used to begin its manufacturing and commercialization process and execute its go-to-market strategy, as well as further the company's talent acquisition efforts.
Company Info
Additional Info
Helaina believes that the inability to breastfeed should not define the health of a child or the worth of a parent. By producing functional proteins through microbial fermentation, Helaina has created a new category of infant milk with natural, immuno-identical proteins that are 99% identical to those found in breastmilk, empowering and equipping parents with better access, more choice, and the ability to provide their children crucial antibacterial, antifungal, and antiviral properties that traditional formula lacks. Helaina has a lab in New York City where the company produces microbes, ferments and runs immunity testing.